Inforlife SA

InfoRLife SA (often referred to as Inforlife SA) is a privately held pharmaceutical company headquartered in Campascio, Switzerland. Founded on January 8, 2002, the company operates as a subsidiary of ACS Dobfar S.p.a., an Italian chemical-pharmaceutical firm. Inforlife SA employs between 21 and 50 people, with an estimated annual revenue of approximately $3.16 million.

The company specializes in the production of pharmaceutical substances, focusing on developing, registering, and manufacturing ready-to-use medicines, often in plastic bags, utilizing sterile methods. Their product lines include finished dosage forms, such as injectables and oral medicines, primarily for hospital use. Inforlife SA maintains its own R&D laboratories and is approved by the USA Food and Drug Administration (FDA) for sales in the United States, which constitutes its primary market. Products include antibiotics like Vancomycin, Levofloxacin, Fluconazole, and Ciprofloxacin. The company also oversees subsidiaries in Romania, Tunisia, and Brazil.

In terms of patent litigation, Inforlife SA exhibits the posture of an operating company defending its intellectual property. The company has no record of initiating patent infringement lawsuits as a plaintiff. Instead, it has been named as a defendant in one tracked case before the Patent Trial and Appeal Board (PTAB).

The single tracked case, an untitled PTAB proceeding from April 2, 2026, lists Inforlife SA as a defendant. This indicates that the company is likely defending the validity of one of its patents against a challenge, a common occurrence for pharmaceutical manufacturers. In 2020, Inforlife SA, along with its parent company ACS Dobfar, was involved in the sale of marketing authorizations for a series of antibiotics for hospital use in the Nordic region to Navamedic ASA.